H
HelixNano
Uses artificial intelligence to help cure genetic diseases
About HelixNano
HelixNano is a biotechnology startup that operates in the field of mRNA (messenger RNA) technology. In simple terms, mRNA is a type of genetic material that our bodies use to build proteins. HelixNano is leveraging this technology to create treatments that are faster, cheaper, and more accessible than traditional methods. Their primary market is the healthcare sector, particularly in the development of vaccines and other medical treatments.
Read full description
The company's business model is based on research and development of mRNA technologies. They aim to reduce the time and cost of experiments, which traditionally take months or years and cost millions, to weeks and thousands. This is achieved by focusing on improving mRNA from first principles, essentially rethinking the way we approach biology.
HelixNano's revenue generation is likely to come from the commercialization of its technologies, either through the sale of developed treatments or through partnerships with other healthcare companies. A recent example of their work is the development of a variant-resistant COVID-19 vaccine candidate, which is currently moving towards clinical trials.
The company values a decentralized and diverse team, believing that every individual scientist can have a significant impact on the company's direction. This approach encourages innovation and the exploration of new ideas, which can lead to the development of powerful technologies.
At a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Cambridge, United States
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 65.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, DNA, Genetics and genomics, Core AI, Genome Engineering
- Technology
- Artificial Intelligence, Deep Tech, Machine Learning, Nanotech
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest May 2025
- Capital deployed
- $0
- Preferred round
- CORPORATE SPINOUT
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2022 | — | — | Yes VC | — |
| SERIES A✓Equity / VC | Mar 2022 | $45M | $180M | Yes VC · Milano Investment Partners | — |
Growth signals
Latest recorded traffic for HelixNano is 730 monthly website visits, up 812.5% over the last three months. HelixNano's team declined 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Y Combinator
Schmidt Futures- SVSVT Ventures
The Venture Collective
MetaPlanet
Series A7 investors entered at this stage
Othman Laraki
SGH Capital
Starlight Ventures
Ari Helgason
Ingvar Helgason
Yes VC
Milano Investment Partners
Other known investors11 additional known investors
Charlie Songhurst
Fifty Years
Foobar
Granpool
Hawktail
Lifeline Ventures
Nicholas Shekerdemian
Nordic Makers
OS Fund
Patrick Schneider-Sikorsky
Tom Vorisek
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about HelixNano on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See HelixNano’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.